Condition
Multiple Myeloma, Relapsed clinical trials and research
Research outlook What's coming for Multiple myeloma: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 2 Multiple Myeloma, Relapsed clinical trials that are recruiting, at sites in 2 countries (most in South Korea (1), Israel (1)). By phase: Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Quality of life and treatment outcomes for relapsed/refractory multiple myeloma with advanced versus conventional immunotherapies.
This will test whether advanced immuno-oncology treatments lead to different quality of life, safety, and treatment outcomes than conventional immunotherapies in adults with relapsed or refractory multiple myeloma.
-
HBI0101 CAR-T therapy for multiple myeloma and light-chain amyloidosis
This study is testing a new CAR-T therapy called HBI0101 to see if it can help people with relapsed or hard-to-treat multiple myeloma and light-chain amyloidosis feel better.
Related topics
Quick answers
How many Multiple Myeloma, Relapsed clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in South Korea (1 trial), Israel (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.